Drug sales for major depressive disorders (MDD) in the US are expected to grow at a compound annual growth rate (CAGR) of 6.6% to reach $4.6bn by 2025, compared to $2.4bn in 2015, according to a report by GlobalData.
Titled 'PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025', the report states attributes the growth to the availability of a wide range of treatments and the commercial success of atypical antipsychotics.
Go deeper with GlobalData
The same factors will help the country to remain the biggest major market for MDD drugs, adds the report.
Antipsychotics accounted for 39% of the MDD drug sales in the US in 2015 and their sales are expected to grow at a CAGR of 7.1% to reach $1.9bn in sales by the end of the forecast period, retaining their market share.
Drugs in the class are currently priced high, resulting in increasing sales of generic aripiprazole.
Abilify was the most-sold atypical antipsychotic in 2015 and its sales are expected to remain flat during the forecast period, due to competition from generics and Otsuka / Lundbeck’s Rexulti.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe report further mentions five MDD drugs that are currently in late-stage pipeline and will enter the US market, which include Alkermes’ ALKS-5461, Allergan / Gedeon Richter / Mitsubishi Tanabe’s Vraylar, Axsome Therapeutics’ AXS-05, Janssen’s esketamine, and Allergan’s rapastinel.
The pipeline drugs are forecast to generate combined sales of more than $800m, led by Janssen’s esketamine, by 2025.
